ALLKのチャート
ALLKの企業情報
| symbol | ALLK |
|---|---|
| 会社名 | Allakos Inc （アラコス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Allakos Inc. is a clinical-stage biotechnology company which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells which are involved in allergy inflammation and tissue damage. Its lead program is AK002 which is an antibody that targets Siglec-8 an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells including eosinophilic gastritis (EG) indolent systemic mastocytosis urticaria and allergic conjunctivitis. アラコスは米国のバイオ医薬品企業。臨床段階で、アレルギ―性疾患、炎症性疾患および増殖性疾患の治療用抗体の開発に従事する。同社は、好酸球性胃炎および胃腸炎、じんま疹、無症候性全身性肥満細胞症、重度のアレルギ―性結膜炎の治療薬AK002を開発する。本社所在地はカリフォルニア州サン・カルロス。 Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. |
| 本社所在地 | 75 Shoreway Road Suite A San Carlos CA 94070 USA |
| 代表者氏名 | Christopher Bebbington Christopher Bebbington |
| 代表者役職名 | President Founder Director |
| 電話番号 | +1 650-597-5002 |
| 設立年月日 | 40969 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.allakos.com |
| nasdaq_url | https://www.nasdaq.com/symbol/allk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.66500 |
| 終値（lastsale） | 32.035 |
| 時価総額（marketcap） | 1349091845.065 |
| 時価総額 | 時価総額（百万ドル） 1485.749 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1564.622 |
| 当期純利益 | 当期純利益（百万ドル） -31.66600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Allakos Inc revenues was not reported. Net loss increased 83% to $17.9M. Higher net loss reflects Research and Development - Balancing increase of 64% to $13.2M (expense) General and Administrative - Balancing increase from $1.4M to $4M (expense) Stock-based Compensation in SGA increase from $86K to $718K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.24 to -$0.43. |
ALLKのテクニカル分析
ALLKのニュース
Cantor Fitzgerald Equities Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK) 2022/05/23 06:01:12 ForexTV
Research analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for shares of Allakos in a research report issued on Thursday, May 19th. Cantor Fitzgerald analyst J. Kim now expects that … Read Full Story at source (may require registration) The post Cantor Fitzgerald Equities Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK) appeared first on ForexTV .
Allakos Inc. (NASDAQ: ALLK) Drops -5.74 Percent In Recent Session, Why Are You Interested? 2022/05/10 12:30:00 Stocks Register
The trading price of Allakos Inc. (NASDAQ:ALLK) closed lower on Monday, May 09, closing at $3.20, -5.74% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $3.05 and … Allakos Inc. (NASDAQ: ALLK) Drops -5.74 Percent In Recent Session, Why Are You Interested? Read More »
5 Stocks To Watch For May 9, 2022 2022/05/09 09:07:20 Benzinga
Some of the stocks that may grab investor focus today are: Wall Street expects Exelon Corporation (NASDAQ: EXC ) to report quarterly earnings at $0.66 per share on revenue of $4.62 billion before the opening bell. Exelon shares rose 0.4% to $47.25 in after-hours trading. Allakos Inc. (NASDAQ: ALLK ) posted a loss of $3.60 per share for the first quarter, versus a year-ago … Full story available on Benzinga.com
Allakos announces $250M shelf offering 2022/05/06 21:36:03 Seeking Alpha
Allakos (ALLK) declines 1.5% during after hours on $250M worth shares shelf offering.Company will determine when they sell shares of our common stock, which may be sold on a continuous…
Allakos GAAP EPS of -$3.60 misses by $1.78 2022/05/06 20:08:33 Seeking Alpha
Allakos press release (ALLK): Q1 GAAP EPS of -$3.60 misses by $1.78.Allakos ended the first quarter of 2022 with $246.7 million in cash, cash equivalents and marketable securities.
Allakos announces $250M shelf offering 2022/05/06 21:36:03 Seeking Alpha
Allakos (ALLK) declines 1.5% during after hours on $250M worth shares shelf offering.Company will determine when they sell shares of our common stock, which may be sold on a continuous…
Allakos GAAP EPS of -$3.60 misses by $1.78 2022/05/06 20:08:33 Seeking Alpha
Allakos press release (ALLK): Q1 GAAP EPS of -$3.60 misses by $1.78.Allakos ended the first quarter of 2022 with $246.7 million in cash, cash equivalents and marketable securities.
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results 2022/05/06 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
CBAY, ALLK and SOND among after hour movers 2022/04/22 21:28:43 Seeking Alpha
Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%
Allakos Inc. (NASDAQ:ALLK) Plunging -94.71% In 6 Months – Here’s What To Expect 2022/03/26 18:00:00 Marketing Sentinel
Allakos Inc. (NASDAQ:ALLK)’s traded shares stood at 0.63 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $5.72, to imply a decrease of -4.03% or -$0.24 in intraday trading. The ALLK share’s 52-week high remains $116.61, putting it -1938.64% down since that peak … Allakos Inc. (NASDAQ:ALLK) Plunging -94.71% In 6 Months – Here’s What To Expect Read More »
Allakos Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover 2022/01/15 01:40:23 Kwhen Finance
Allakos Inc (ALLK) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $426M. The stock is currently down 19.8% year-to-date, down 93.6% over the past 12 months, and down 74.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 77.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 236.3% The company's stock price performance over the past 12 months lags the peer average by 358.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Why Allakos Stock Plummeted 87.5% in the Last Month of 2021 2022/01/06 13:17:06 The Motley Fool
The biotech stock is now down roughly 93% over the last year.
Allakos Inc Shares Close the Day 22.2% Higher - Daily Wrap 2021/12/27 09:55:48 Kwhen Finance
Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 52.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Allakos Inc Shares Close the Day 22.2% Higher - Daily Wrap 2021/12/26 11:01:01 Kwhen Finance
Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 89.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The Goldman Sachs Group Lowers Allakos (NASDAQ:ALLK) Price Target to $60.00 2021/12/24 09:18:41 Transcript Daily
Allakos (NASDAQ:ALLK) had its target price decreased by The Goldman Sachs Group from $122.00 to $60.00 in a research report report published on Thursday morning, Analyst Ratings Network reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other analysts have also commented on ALLK. Jefferies Financial Group lowered []